Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.